Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian

Viviana Cortiana1, Rabab Hunaid Abbas2, Harshal Chorya3

  • 1Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy.

Cancers
|July 13, 2024

Related Experiment Videos

View abstract on PubMed

Summary

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Personalized Medicine In Pancreatic Cancer: The Promise Of Biomarkers And Molecular Targeting With Dr. Michael J. Pishvaian
    • This summary is machine-generated.

    Pancreatic cancer urgently needs better diagnostics and treatments. Biomarkers and molecular classification offer personalized strategies, improving outcomes for this deadly disease.

    Area of Science:

    • Oncology
    • Genomics
    • Molecular Biology

    Background:

    • Pancreatic cancer incidence is rising, projected to be the second deadliest solid tumor by 2040.
    • Current five-year survival rates are low (around 14%), decreasing significantly with metastasis.
    • There is a critical need for advanced diagnostic and therapeutic approaches.

    Purpose of the Study:

    • To review the role of biomarkers in early detection, personalized treatment, and monitoring of pancreatic cancer.
    • To explore how molecular classification aids in guiding treatment decisions.
    • To highlight the potential of targeted therapies and advanced sequencing technologies.

    Main Methods:

    • Literature review focusing on biomarkers, molecular classification, and targeted therapies for pancreatic cancer.
    • Discussion of Next-Generation Sequencing (NGS) applications in genomic analysis.
    • Analysis of ongoing clinical trials and emerging therapeutic strategies.

    Main Results:

    • Biomarkers show promise for early detection, personalized treatment, and disease monitoring.
    • Molecular subtyping based on genetic, gene expression, and protein markers can guide treatment.
    • Targeted therapies (e.g., against CLAUDIN 18.2) and NGS are advancing personalized oncology.

    Conclusions:

    • Biomarker-guided therapies and molecularly tailored treatments are crucial for improving pancreatic cancer outcomes.
    • Continued research into molecular mechanisms is essential for developing more effective treatments.
    • Addressing challenges in awareness and uptake of biomarker-guided therapies is necessary.
    Keywords:
    biomarkersearly detectiongenetic mutationsgermline testingnext-generation sequencing (NGS)pancreatic cancerpersonalized medicine

    Related Experiment Videos